RYBREVANT FASPRO™ Receives FDA Approval for First-Line EGFR-Mutated NSCLC
December 26, 2025
Brand Name :
Bronco-plus
Synonyms :
Stepronino, Tiofacic, Stepronine, Steproninum
Class :
Expectorant, Mucolytic
Adult
Dosage Forms & Strengths
It is used as an investigational and research purpose
Solution (inhalation)
810 mg
Respiratory disorders (off-label)
In a study with ten healthy volunteers, they took stepronine lysine salt, a drug that helps thin mucus, for ten days at 810 mg per day
The study found that this treatment did not change the amount or quality of mucous in the stomach
The results suggest that stepronine’s mucus-thinning effect doesn’t impact the stomach’s mucous lining and doesn’t cause harm to the stomach
Dose Modifications
Limited data is available
Pediatric
Safety and efficacy are not seen in pediatrics
Geriatric
Refer to the adult dosing
the danger or seriousness of adverse effects can be heightened when abatacept is combined with strepronin
the peril or acuteness of adverse effects can be increased when alefacept is combined with stepronin
the peril or acuteness of adverse effects can be increased when adalimumab is combined with stepronin
the jeopardy or severity of infection can be magnified when adenovirus type 7 vaccine live is combined with stepronin
the threat or seriousness of adverse effects can be boosted when aldesleukin is combined with stepronin
the danger or seriousness of adverse effects can be heightened when vinorelbine is combined with stepronin
the peril or acuteness of adverse effects can be elevated when stepronin is combined with voclosporin
the danger or seriousness of adverse effects can be increased when stepronin is combined with vorinostat
the risk or severity of infection can be magnified when yellow fever vaccine is combined with stepronin
the threat or acuteness of adverse effects can be heightened when zidovudine is combined with stepronin
Actions and Spectrum
Thick bronchial secretions can be loosened with the help of mucolytics, where as expectorants tend to increase secretions. Expectorants thin or viscosify bronchial secretions, making it easier for mucus to be expelled by coughing. Mucolytics alter the molecular makeup of mucus molecules. Coughing facilitates the easier removal of mucus because it thins.
Limited data is available
Black Box Warning:
Contraindication/Caution:
Contraindications
Cautions
Pregnancy consideration:
No data is available regarding the administration of the drug during pregnancy.
Breastfeeding warnings:
No data is available regarding the excretion of drug in breast milk.
Pregnancy categories:
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.
<b>Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: No data is available for the drug under this category.
Pharmacology
It acts as mucolytic and expectorant.Expectorants are used to drainout the bronchial secretions in the form of mucus while coughing. Whereas mucolytics aids in loosening the thickened secretions
Pharmacodynamics
The drug decreases the amount of mucus and lubricates the swollen respiratory tract, which helps it to drain from the lungs.
Pharmacokinetics
Limited information available
Administration
Not available
Patient information leaflet
Generic Name: stepronin
Pronounced: steh-proh-nin
Why do we use stepronin?
Strepronin acts as a mucolytic and expectorant in treating several respiratory disorders such as bronchitis.